We are a publicly traded (NASDAQ:"ALIM") biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. Our efforts are currently focused on diseases affecting the lining in the back of the eye, or retina, because these diseases are either not treated pharmacologically or are in need of improved treatments. As the world’s population continues to age, more and more people will be afflicted by these diseases. We created Alimera in June 2003, with the vision to bring innovative products to treat eye disease, specifically diseases that affect the retina, and to be guided by our experience of knowing the right things to do and our desire to “do the right thing” in our daily approach to the business. We invite you to learn more about us through our website.